2026 Serge Muyldermans: Biology and Biochemistry Researcher – H-Index, Publications & Awards

D-Index & Metrics

Discipline name	D-Index	World Ranking	Current World Ranking	National Ranking	Current National Ranking	Publications	Citations
Biology and Biochemistry	101	1420	1278	23	22	427	43428

Discipline name

D-Index

World Ranking

Current World Ranking

National Ranking

Current National Ranking

Publications

Citations

Biology and Biochemistry

101

1420

1278

427

43428

Biology and Biochemistry

D-Index

101

Citations

43428

World Ranking

1420

National Ranking

Research.com Recognitions

2023 - Research.com Biology and Biochemistry in Belgium Leader Award

Overview

Serge Muyldermans is affiliated with Vrije Universiteit Brussel in Belgium and has contributed extensively to the fields of medicine and biochemistry, genetics, and molecular biology. Their research predominantly focuses on the study and application of antibodies, particularly nanobodies, as reflected in their significant number of publications.

Their recent research papers include:

Applications of Nanobodies, 2020, Annual Review of Animal Biosciences
A guide to: generation and design of nanobodies, 2020, FEBS Journal
Immunogenicity Risk Profile of Nanobodies, 2021, Frontiers in Immunology
Animal Immunization, in Vitro Display Technologies, and Machine Learning for Antibody Discovery, 2021, Trends in Biotechnology
An overview on display systems (phage, bacterial, and yeast display) for production of anticancer antibodies; advantages and disadvantages, 2022, International Journal of Biological Macromolecules

Frequent co-authors collaborating with Serge Muyldermans include:

Cécile Vincke
Nick Devoogdt
Ema Romão
Yaozhong Hu
Mohamed Sallam

The main fields of study addressed in their work span:

Medicine
Biochemistry, Genetics and Molecular Biology

Within these, subfields frequently explored are:

Molecular Biology
Radiology, Nuclear Medicine and Imaging
Immunology
Biomedical Engineering
Immunology and Allergy

Serge Muyldermans's research covers key topics such as:

Monoclonal and Polyclonal Antibodies Research
Glycosylation and Glycoproteins Research
Biochemical and Structural Characterization
Food Allergy and Anaphylaxis Research
Advanced biosensing and bioanalysis techniques
Galectins and Cancer Biology
Protein purification and stability

Their work has been published frequently in venues including:

Frontiers in Immunology
International Journal of Molecular Sciences
Journal of Agricultural and Food Chemistry
Biomolecules
bioRxiv (Cold Spring Harbor Laboratory)

Best Publications

Naturally occurring antibodies devoid of light chains

Hamers-Casterman C;Atarhouch T;Muyldermans S;Robinson G

3800
Citations
Nanobodies: Natural Single-Domain Antibodies

Serge Muyldermans

2151
Citations
Selection and identification of single domain antibody fragments from camel heavy-chain antibodies

M Arbabi Ghahroudi;A Desmyter;L Wyns;R Hamers

1092
Citations
Single domain camel antibodies: current status.

Serge Muyldermans

962
Citations
A general protocol for the generation of Nanobodies for structural biology

Els Pardon;Toon Laeremans;Sarah Triest;Søren G F Rasmussen

868
Citations
Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies.

Erwin De Genst;Karen Silence;Klaas Decanniere;Katja Conrath

804
Citations
Single-domain antibody fragments with high conformational stability

Mireille Dumoulin;Katja Conrath;Annemie Van Meirhaeghe;Filip Meersman

799
Citations
A Versatile Nanotrap for Biochemical and Functional Studies with Fluorescent Fusion Proteins

Ulrich Rothbauer;Kourosh Zolghadr;Serge Muyldermans;Aloys Schepers

798
Citations
Targeting and tracing antigens in live cells with fluorescent nanobodies

Ulrich Rothbauer;Kourosh Zolghadr;Sergey Tillib;Danny Nowak

778
Citations
Crystal structure of a camel single-domain VH antibody fragment in complex with lysozyme

Aline Desmyter;Thomas R. Transue;Mehdi Arbabi Ghahroudi;Minh-Hoa Dao Thi

714
Citations
Sequence and structure of VH domain from naturally occurring camel heavy chain immunoglobulins lacking light chains

Serge Muyldermans;Touriya Atarhouch;J. Saldanha;Jorg.a.r.g. Barbosa

698
Citations
Camelid immunoglobulins and nanobody technology.

S. Muyldermans;T.N. Baral;V. Cortez Retamozzo;P. De Baetselier

646
Citations
Potent enzyme inhibitors derived from dromedary heavy‐chain antibodies

Marc Lauwereys;Mehdi Arbabi Ghahroudi;Aline Desmyter;Jörg Kinne

645
Citations
The Therapeutic Potential of Nanobodies

Ivana Jovčevska;Serge Muyldermans

630
Citations
Modulation of protein properties in living cells using nanobodies

Axel Kirchhofer;Jonas Helma;Jonas Helma;Katrin Schmidthals;Katrin Schmidthals;Carina Frauer;Carina Frauer

621
Citations
General Strategy to Humanize a Camelid Single-domain Antibody and Identification of a Universal Humanized Nanobody Scaffold

Cécile Vincke;Remy Loris;Dirk Saerens;Dirk Saerens;Sergio Martinez-Rodriguez

608
Citations
Efficient Cancer Therapy with a Nanobody-Based Conjugate

Virna Cortez-Retamozo;Natalija Backmann;Peter D. Senter;Ullrich Wernery

519
Citations
Nanobody-based products as research and diagnostic tools.

Thomas De Meyer;Serge Muyldermans;Anna Depicker

508
Citations
Recognition of antigens by single-domain antibody fragments: the superfluous luxury of paired domains

Serge Muyldermans;Christian Cambillau;Lode Wyns

476
Citations
Comparison of llama VH sequences from conventional and heavy chain antibodies

Khoa Bang Vu;Mehdi Arbabi Ghahroudi;Lode Wyns;Serge Muyldermans

464
Citations